WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc
(NASDAQ: GWPH) and others conducting clinical trials targeting
important indications like cancer pain and arthritis, the data collected
so far has suggested that cannabinoids could have far-reaching
beneficial effects on the human body.
InMed Pharmaceuticals Inc.
(OTC: IMLFF), a clinical-stage drug discovery and development company
focused on the therapeutic potential of cannabinoids, recently announced
that it retained Tiberend Strategic Advisors to manage its investor and
public relations programs. The New York-based corporate communications
firm specializes in emerging healthcare companies.
In a recent article appearing in The Scientist,
InMed Pharmaceuticals' President and CEO Craig Schneider outlined why
the company was focusing on the biotech side of the business: "We looked
at GW and saw that the shift toward pharmacological development of
marijuana is already happening … we see the likes of Otsuka, Novartis,
and Eli Lilly diving into the space and we want to be part of that."
Focus on Biotech
Tiberend Strategic Advisors is a full service corporate
communications firm that has made a name for itself in the healthcare
and life sciences industry. Founded in 1989, the firm's mission is to
provide expert public and investor relations counsel to companies along
the entire development lifecycle - from emerging, clinical-stage to
publicly-traded and revenue generating companies in the space.
Within the biotech industry, Tiberend sponsors a number of conferences including Sachs Associates' Cancer Bio Partnering & Investment Forum, Biotech Showcase, and the Bio CEO & Investor Conference. The firm's clients include notably companies from $200+ million market capitalization companies, like Galena Biopharma Inc. (NASDAQ: GALE), to smaller companies like Advaxis Inc. (NASDAQ: ADXS).
Gregory Tiberend heads the team at Tiberend Strategic Advisors with
many years of experience in both the public relations and healthcare
industry. Over his career, Mr. Tiberend has counseled more than 50
companies in the areas of biotechnology, specialty pharmaceutical,
generic pharmaceutical, medical service, diagnostics, healthcare
services, and financial services, among others.
Taking a Unique Approach
InMed Pharmaceuticals' hiring of Tiberend Strategic Advisors
highlights its focus on the biotech side of the cannabis industry. By
leveraging its proprietary Intelligent Cannabinoid Drug Design Platform,
the company aims to rapidly identify promising new bioactive compounds
in cannabis and create an accelerated pathway for drug development and
commercialization of between three and five years.
So far, the company has identified two compounds to treat glaucoma
and arthritis, known as CTI-085 and CTI-091, respectively. CTI-085 is a
topical formulation containing a proprietary cannabinoid compound along
with non-cannabis ingredients, while CTI-091 is a mixture of
cannabinoids and non-cannabis ingredients to relieve joint pain and
swelling from arthritis.
Through a partnership with researchers at the University of British
Columbia, the company is also developing a drug delivery system that
effectively transports these therapies to the intended tissue without
significant dilution. Cannabinoids have traditionally been difficult to
deliver due to their lipophilic nature - which leads to them combining
with lipids or fats in the body before reaching a target.
Looking Ahead
InMed Pharmaceuticals is rapidly moving forward with its clinical
programs with the help of its proprietary platform. President & CEO
Craig Schneider heads the company with over 20 years of capital markets
experience, while CSO Dr. Sazzad Hossain, Ph.D., M.Sc., has over 20
years of experience with new drug development and a history with the
Biotechnology Research Institute in Canada.
In addition to its clinical programs, the company has started
developing individual strains and clones that will produce raw material
for future research. The team will study plant development and secondary
metabolite biosynthesis in both indoor and outdoor conditions that meet
high quality standards. These efforts are similar to GW Pharma's Cannabinoid Research Institute programs.
With a market capitalization of just over $6 million, investors in
both the cannabis and biotech industries may want to take a closer look
at the stock. Management's industry expertise and the company's
proprietary platform could set the stage for drug discovery and
development that takes less than five years instead of more than 10
years - yielding a nearer term opportunity in a rapidly growing niche
market.
Click here to learn more about InMed Pharma, which recently changed its name from Cannabis Technologies: http://www.cannabisfn.com/mdc/cannabis-technologies-inc/.
Legal Disclaimer
Except for the historical
information presented herein, matters discussed in this article contain
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from
any future results, performance or achievements expressed or implied by
such statements. Emerging Growth LLC dba TDM Financial, which owns
CannabisFN, is not registered with any financial or securities
regulatory authority, and does not provide nor claims to provide
investment advice or recommendations to readers of this release.
Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from
time to time have a position in the securities mentioned herein and may
increase or decrease such positions without notice. For making specific
investment decisions, readers should seek their own advice. Emerging
Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated
for its services in the form of cash-based compensation or equity
securities in the companies it writes about, or a combination of the
two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
SOURCE: Emerging Growth LLC